Pharmaceuticals
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model
SYDNEY, Aug. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBP...
2021-08-05 18:00
1996
KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for Filing in Japan
TAIPEI, Aug. 5, 2021 /PRNewswire/ -- KYOWA Pharmaceutical Industry Co. Ltd., a premier Japanese pharmaceutical company, has contracted with Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals for the manufacturing of generic product for filing inJapan. KYOWA will be...
2021-08-05 14:50
2734
Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia
SHANGHAI, Aug. 5, 2021 /PRNewswire/ -- Everest Medicines
2021-08-05 13:12
5208
Chinese Multinational Technology Company, HUAWEI, Aligns With Singapore-Based Healthtech Start-up PLANO to Tackle the Global Problem of Myopia
SINGAPORE, Aug. 5, 2021 /PRNewswire/ -- Shenzhen, Guangdong, China, and Singapore – Huawei Technologies Co. Ltd. (hereinafter, Huawei) and Plano Pte. Ltd. (hereinafter, Plano) today announced their partnership to address the global problem of myopia. Through this partnership, Huawei and Plano wil...
2021-08-05 10:00
3032
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
GAITHERSBURG, Md., Aug. 4, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses...
2021-08-04 21:10
10479
Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine
HONG KONG, Aug. 4, 2021 /PRNewswire/ -- Insilico Medicine, a global company specializing in the applications of the next-generation machine learning technologies for drug discovery and development, announced today that its AI-powered drug discovery platform had delivered the preclinical candidate...
2021-08-04 18:11
3262
Lumosa Therapeutics Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke
* LT3001 met primary safety endpoint. No symptomatic intracranial hemorrhage occurred. * LT3001 showed pronounced neurological improvement in the majority of patients with baseline NIHSS≥6 treated with LT3001. * These data suggest that LT3001 has the potential to provide significant clinica...
2021-08-03 22:48
2759
Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®
SEOUL, South Korea, Aug. 3, 2021 /PRNewswire/ -- Yuyu Pharma, a pharmaceutical company based in Korea, and Novartis Korea announced today that the companies have entered into an agreement in which Yuyu will have exclusive distribution rights for the following prescription medicines in Korea: Lami...
2021-08-03 21:00
2686
111, Inc. Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China
SHANGHAI, Aug. 3, 2021 /PRNewswire/ – 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced a strategic cooperation agreement with Suzhou Zelgen ...
2021-08-03 20:00
8393
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans
Yvelise Barrios, MD, PhD, Immunologist and leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behindCoviDTH, joins BioVaxys as scientific adviser VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (C...
2021-08-03 20:00
6093
TCM Lianhua Qingwen shows stable in vitro antiviral effect on the Delta variant: Expert
GUANGZHOU, China, Aug. 3, 2021 /PRNewswire/ -- The latest research findings from the team of Professor Yang Zifeng from the State Key Laboratory of Respiratory Disease inGuangzhou, China, have showed that Chinese medicine Lianhua Qingwen has an effective inhibitory action on the Delta variant of ...
2021-08-03 15:27
3119
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor
BEIJING, Aug. 3, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 inChina. JAB-21822 is Jacobio's innovative in-house small molecule anti-cancer drug, which is designed to target t...
2021-08-03 09:00
4665
Insilico Medicine and Westlake Pharma Announce Cooperation Relationship on Accelerating the Innovative Drugs R&D for Novel Coronavirus
HANGZHOU, China, Aug. 3, 2021 /PRNewswire/ -- Insilico Medicine and Westlake
Pharma announced a strategic partnership to jointly develop innovative
small-molecule drugs for Novel Coronavirus (COVID-19) today.
2021-08-03 08:00
35810
SI Group Ranks in the Top 5 Percent for Global Corporate Social Responsibility
Company Awarded Gold Rating by EcoVadis for its Sustainability Commitment SCHENECTADY, N.Y., Aug. 2, 2021 /PRNewswire/ -- SI Group, a global leader in the innovative technology of performance additives, process solutions, active pharmaceutical ingredients, and chemical intermediates, has received...
2021-08-02 22:33
3610
Bionomics Announces Plans to Conduct U.S. Initial Public Offering
ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United ...
2021-08-02 18:00
14575
Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
TIBSOVO is the first targeted therapy to show improved event-free survival and overall survival in combination with azacitidine compared to azacitidine monotherapy. Safety profile consistent with previously published data in patients with IDH1-mutated acute myeloid leukemia. The study recently ...
2021-08-02 14:00
3308
LISCure Biosciences Announces Know-How License Agreement and Stock Purchase Agreement with Mayo Clinic
SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered into a know-how license and development collaboration agreement, and stock purchase agreement with Mayo Clinic to advance LISCure's microbiome therapeutics in non-alcoholic steatohepatitis (NASH). ...
2021-08-02 11:11
1848
Luye Pharma Enters Distribution Agreement with Zuellig Pharma for Seroquel and Seroquel XR in Malaysia and Brunei, Strengthening Business Presence in Asia Pacific and Improving Access to Evidence-Based Medical Treatments for Mental Health
SUBANG JAYA, Malaysia, Aug. 2, 2021 /PRNewswire/ -- Luye Pharma Group today announced that it has entered into an agreement with Zuellig Pharma, a leading healthcare service group inAsia, under which the company grants Zuellig Pharma exclusive rights to distribute its central nervous system drugs...
2021-08-02 10:25
5497
Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
SEOUL, South Korea and SHANGHAI and HONG KONG, Aug. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics i...
2021-08-02 07:29
6383
Appendix 4C - Q4 FY21 Quarterly Cash Flow Report
Highlights: * Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial * Publication in Movement Disorders demonstrates that ATH434 reduces α–synuclein related neurodegeneration in MSA animal model * Presents to MST Access Australian Micro & Small Caps Conference ...
2021-07-30 21:05
15602
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
PT Telkom Indonesia (Persero) Tbk 2025 Annual Report on Form 20-F
2026-05-16 00:26
7986
Eyes that photosynthesise: NUS scientists plant a cure for dry eye disease
2026-05-16 11:14
6013
Lepro Introduces STV1, a TV Backlight That Combines Screen Sync, AI Lighting, and Easier Setup
2026-05-16 00:00
5785
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
5493
